EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The genomic landscape of breast and non-breast cancers from individuals with germline CHEK2 deficiency

Snežana Hinić, Rachel S van der Post, Lilian Vreede, Janneke Schuurs-Hoeijmakers, Saskia Koene, Erik A M Jansen, Franziska Bervoets-Metge, Arjen R Mensenkamp iD, Nicoline Hoogerbrugge iD, Marjolijn J L Ligtenberg, Richarda M de Voer iD

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Snežana Hinić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Checkpoint Kinase 2, Germ-Line Mutation, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CHEK2 is considered to be involved in homologous recombination repair (HRR). Individuals who have germline pathogenic variants (gPVs) in CHEK2 are at increased risk to develop breast cancer and likely other primary cancers. PARP inhibitors (PARPi) have been shown to be effective in the treatment of cancers that present with HRR deficiency—for example, caused by inactivation of BRCA1/2. However, clinical trials have shown little to no efficacy of PARPi in patients with CHEK2 gPVs. Here, we show that both breast and non-breast cancers from individuals who have biallelic gPVs in CHEK2 (germline CHEK2 deficiency) do not present with molecular profiles that fit with HRR deficiency. This finding provides a likely explanation why PARPi therapy is not successful in the treatment of CHEK2-deficient cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Checkpoint Kinase 2Germ-Line MutationBreast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleMaleNeoplasmsOvarian NeoplasmsMiddle AgedRecombinational DNA RepairAdultBreast Neoplasms, Male

Substanzen

Checkpoint Kinase 2CHEK2 protein, humanPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.
  • Department of Pathology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.

ORCID-Profile: Arjen R Mensenkamp, Nicoline Hoogerbrugge, Richarda M de Voer

Förderung

  • Dutch Cancer Society

Zitieren

APA

Hinić, S., van der Post, R. S., Vreede, L., Schuurs-Hoeijmakers, J., Koene, S., Jansen, E. A. M., Bervoets-Metge, F., Mensenkamp, A. R., Hoogerbrugge, N., Ligtenberg, M. J. L., & de Voer, R. M. (2024). The genomic landscape of breast and non-breast cancers from individuals with germline CHEK2 deficiency. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae044

Vancouver

Hinić S, van der Post RS, Vreede L, Schuurs-Hoeijmakers J, Koene S, Jansen EAM, et al. The genomic landscape of breast and non-breast cancers from individuals with germline CHEK2 deficiency. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae044

BibTeX
@article{Hini2024,
  author = {Hinić, Snežana and van der Post, Rachel S and Vreede, Lilian and Schuurs-Hoeijmakers, Janneke and Koene, Saskia and Jansen, Erik A M and Bervoets-Metge, Franziska and Mensenkamp, Arjen R and Hoogerbrugge, Nicoline and Ligtenberg, Marjolijn J L and de Voer, Richarda M},
  title = {The genomic landscape of breast and non-breast cancers from individuals with germline CHEK2 deficiency},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae044}
}
Kostenlos starten →